N/A
N=8
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
GVHD · Ocular Rosacea · Dry Eye Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT02066051 ↗Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Nov 2015
Primary outcome: Primary: Number of Participants Who Responded to Intense Pulsed Light (IPL) — 5; 2 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- IPL (Device); Meibomian Gland Expression (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Nov 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Responded to Intense Pulsed Light (IPL) |
5; 2 | — |
| SECONDARY Number of Participants Who Experienced Adverse Events |
— | — |
Summary
The purpose of this study was to see if Intense Pulsed Light (IPL) can be used safely and effectively to help treat dry eyes from ocular rosacea after chronic graft-versus-host disease (GVHD). Current treatment options for this disease are limited.
Eligibility Criteria
Inclusion Criteria
- Ocular rosacea with inactive GVHD
Exclusion Criteria
- Active GVHD
- Facial laser treatment
- Accutane exposure
- Inability to wear sun protection factor (SPF) 30 sunscreen and avoid sun exposure
- Inability to meet study requirements
Data sourced from ClinicalTrials.gov (NCT02066051). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.